206 related articles for article (PubMed ID: 20574442)
1. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
3. Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity.
Matos I; Mizenina O; Lubkin A; Steinman RM; Idoyaga J
PLoS One; 2013; 8(6):e67453. PubMed ID: 23840706
[TBL] [Abstract][Full Text] [Related]
4. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
Gurunathan S; Stobie L; Prussin C; Sacks DL; Glaichenhaus N; Iwasaki A; Fowell DJ; Locksley RM; Chang JT; Wu CY; Seder RA
J Immunol; 2000 Jul; 165(2):915-24. PubMed ID: 10878366
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens.
Berberich C; Ramírez-Pineda JR; Hambrecht C; Alber G; Skeiky YA; Moll H
J Immunol; 2003 Mar; 170(6):3171-9. PubMed ID: 12626575
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
[TBL] [Abstract][Full Text] [Related]
8. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.
Stobie L; Gurunathan S; Prussin C; Sacks DL; Glaichenhaus N; Wu CY; Seder RA
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8427-32. PubMed ID: 10890924
[TBL] [Abstract][Full Text] [Related]
9. Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection.
Colmenares M; Kima PE; Samoff E; Soong L; McMahon-Pratt D
Infect Immun; 2003 Jun; 71(6):3172-82. PubMed ID: 12761096
[TBL] [Abstract][Full Text] [Related]
10. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major.
Soussi N; Milon G; Colle JH; Mougneau E; Glaichenhaus N; Goossens PL
Infect Immun; 2000 Mar; 68(3):1498-506. PubMed ID: 10678966
[TBL] [Abstract][Full Text] [Related]
11. Protection and immunological study on two tetraspanin-derived vaccine candidates against schistosomiasis japonicum.
Chen L; Chen Y; Zhang D; Hou M; Yang B; Zhang F; Zhang W; Luo X; Ji M; Wu G
Parasite Immunol; 2016 Oct; 38(10):589-98. PubMed ID: 27189226
[TBL] [Abstract][Full Text] [Related]
12. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.
Stober CB; Lange UG; Roberts MT; Alcami A; Blackwell JM
J Immunol; 2005 Aug; 175(4):2517-24. PubMed ID: 16081824
[TBL] [Abstract][Full Text] [Related]
13. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
[TBL] [Abstract][Full Text] [Related]
14. High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.
Sánchez-Sampedro L; Gómez CE; Mejías-Pérez E; Sorzano CO; Esteban M
PLoS One; 2012; 7(6):e38859. PubMed ID: 22715418
[TBL] [Abstract][Full Text] [Related]
15. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
16. Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice.
Martínez-López M; Iborra S; Conde-Garrosa R; Sancho D
Eur J Immunol; 2015 Jan; 45(1):119-29. PubMed ID: 25312824
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.
Sjölander A; Baldwin TM; Curtis JM; Bengtsson KL; Handman E
Vaccine; 1998 Dec; 16(20):2077-84. PubMed ID: 9796067
[TBL] [Abstract][Full Text] [Related]
18. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
[TBL] [Abstract][Full Text] [Related]
19. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
20. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
